ReviewFrontiers in medicine2022
Small Airways: The "Silent Zone" of 2021 GINA Report?
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06509659 (Methacholine Challenge Test), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Methacholine Challenge Test (MCT) in Healthy Adults: Oscillometry Measured Alone Compared to Oscillometry and FEV1 During the Same Test
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule.The European respiratory journal · 2025Trial
- Small airway dysfunction as a functional barrier to spirometry-defined clinical remission in severe asthma treated with biologic therapies.The World Allergy Organization journal · 2026Article
- The silent zone of paediatric asthma: integrating small airway dysfunction assessment into clinical practice.EClinicalMedicine · 2026Review
- Phenotyping treatment-naive uncontrolled asthma in adults: A primary care framework.The journal of allergy and clinical immunology. Global · 2026Article
- Improvements in small airway dysfunction and respiratory symptoms following tezepelumab for severe asthma.ERJ open research · 2026Article
- Current use and future potential of oscillometry in UK lung function testing: a national survey.BMJ open respiratory research · 2026Article
- Treatable traits of small airway dysfunction in children with asthma and advances in small airway-targeted therapeutic research: a narrative review.Translational pediatrics · 2026Review
- Beyond symptoms: uncovering type 2 inflammation and small airway dysfunction in Treatment-Naïve asthma.BMC pulmonary medicine · 2026Article
- Interpreting respiratory oscillometry in adults with asthma or COPD: findings of an international Delphi study.ERJ open research · 2025Article
- Clinical and demographic characteristics of patients presenting with post-infectious bronchial hyperresponsiveness at a pulmonology clinic.Frontiers in medicine · 2025Article
- Switching from multiple-inhaler triple therapy to single, extrafine-inhaler triple therapy in severe refractory asthma with EGPA: beyond control. Case report and review of the literature.Drugs in context · 2025Article
- The prevalence of small airways disease and association with handgrip strength in young Hispanic farmworkers.BMC pulmonary medicine · 2024Article
- Repositioning baloxavir marboxil as VISTA agonist that ameliorates experimental asthma.Cell biology and toxicology · 2024Article
- Asthma Inflammatory Phenotypes: How Can We Distinguish Them?Journal of clinical medicine · 2024Article
- Small airway dysfunction measured by impulse oscillometry is associated with exacerbations and poor symptom control in patients with asthma treated in a tertiary hospital subspecialist airways disease clinic.Frontiers in allergy · 2024Article
- Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma.Asthma research and practice · 2022Review
- Extrafine formulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurized metered-dose inhaler in the treatment of asthma: a review.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a chronic disease, affecting approximately 350 million people worldwide. Inflammation and remodeling in asthma involve the large airways, and it is now widely accepted that the small airways (those with an internal diameter <2 mm) are involved in the pathogenesis of asthma and are the major determinant of airflow obstruction in this disease. From a clinical perspective, small airways dysfunction (SAD) is associated with more severe bronchial hyperresponsiveness, worse asthma control and more exacerbations. Unlike the GOLD guidelines which, in their definition, identify COPD as a disease of the small airways, the Global Initiative for Asthma (GINA) guidelines do not refer to the prevalence and role of SAD in asthmatic patients. This decision seems surprising, given the growing body of compelling evidence accumulating pointing out the high prevalence of SAD in asthmatic patients and the importance of SAD in poor asthma control. Furthermore, and remarkably, SAD appears to possess the characteristics of a treatable pulmonary trait, making it certainly appealing for asthma control optimization and exacerbation rate reduction. In this mini-review article, we address the most recent evidence on the role of SAD on asthma control and critically review the possible inclusion of SAD among treatable pulmonary traits in international guidelines on asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.